Bio-Rad Laboratories, Inc. (BIO) Financials
BIO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 10.3 billion | 3.1 billion |
| March 31, 2026 | 9.8 billion | 2.9 billion |
| Dec. 31, 2025 | 10.6 billion | 3.1 billion |
| Sept. 30, 2025 | 9.7 billion | 3.0 billion |
BIO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 66.7 million | 14.5 million |
| March 31, 2026 | 78.1 million | 15.0 million |
| Dec. 31, 2025 | 119.1 million | 15.9 million |
| Sept. 30, 2025 | 89.2 million | 14.9 million |
BIO Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| June 30, 2026 | -13.3 million |
| March 31, 2026 | -527.1 million |
| Dec. 31, 2025 | 720.0 million |
| Sept. 30, 2025 | -341.9 million |
BIO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 1.6 billion | 803.0 million | 166.7 million |
| March 31, 2026 | 1.6 billion | 794.3 million | 183.4 million |
| Dec. 31, 2025 | 1.5 billion | 1.3 billion | 154.4 million |
| Sept. 30, 2025 | 1.4 billion | 1.2 billion | 164.6 million |
BIO Shares Outstanding
BIO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 32.0 million | 61.2 million | 212.0 million | - |
| March 31, 2026 | 30.0 million | 62.9 million | 212.4 million | - |
| Dec. 31, 2025 | 45.8 million | 65.7 million | 216.6 million | - |
| Sept. 30, 2025 | 31.7 million | 71.3 million | 206.8 million | - |
BIO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 651.0 million | 305.2 million |
| March 31, 2026 | 592.1 million | 282.7 million |
| Dec. 31, 2025 | 693.2 million | 348.0 million |
| Sept. 30, 2025 | 653.0 million | 309.6 million |
BIO Revenue by Segment
Graph available only for paid members. Upgrade to see it.
BIO
Price: $356.26
52 week price:
Payout Ratio Range:
Earnings Per Share: 8.26 USD
P/E Ratio: 42.92
Exchange: NYQ
Sector: Healthcare
Industry: Medical Devices
Country: United States
Volume: 92800
Ebitda: 79.8 millionMarket Capitalization: 9.5 billion